zifeng-ai/TrialReviewBench huggingface dataset:
Study design: Randomized phase 2
Number of patients: 83
Tyrosine kinase inhibitor: Sorafenib
Age in tyrosine kinase inhibitor group (range): 54 (23–74)
Comparator: Placebo
Myeloablative conditioning: tyrosine kinase inhibitor: 42%, Placebo: 47%
Complete remission at transplant: tyrosine kinase inhibitor: 63%, placebo: 48%
High-risk cytogenetics: tyrosine kinase inhibitor: 2%, Placebo: 8%
Length of follow-up: 42 months
Study design: Retrospective
Number of patients: 81
Tyrosine kinase inhibitor: Sorafenib
Age in tyrosine kinase inhibitor group (range): 55 (20–74)
Comparator: No tyrosine kinase inhibitor
Myeloablative conditioning: tyrosine kinase inhibitor: 54%, No: 49%
Complete remission at transplant: 100% (CR1)
High-risk cytogenetics: 8%
Length of follow-up: 27 months
Study design: Prospective phase 2, propensity score matching with historical controls
Number of patients: 116a
Tyrosine kinase inhibitor: Midostaurin
Age in tyrosine kinase inhibitor group (range): 54 (18–70)
Comparator: Historical control
Myeloablative conditioning: not reported
Complete remission at transplant: tyrosine kinase inhibitor: 61%, control: 43%
High-risk cytogenetics: not reported
Length of follow-up: 24 months
Study design: Randomized phase 3
Number of patients: 202
Tyrosine kinase inhibitor: Sorafenib
Age in tyrosine kinase inhibitor group (range): 35 (26–42)
Comparator: No tyrosine kinase inhibitor
Myeloablative conditioning: 100%
Complete remission at transplant: tyrosine kinase inhibitor: 73%, no: 77%
High-risk cytogenetics: tyrosine kinase inhibitor: 7%, no: 5%
Length of follow-up: 21 months
Study design: Retrospective
Number of patients: 82
Tyrosine kinase inhibitor: Sorafenib
Age in tyrosine kinase inhibitor group (range): 37 (15–55)
Comparator: No tyrosine kinase inhibitor
Myeloablative conditioning: 100%
Complete remission at transplant: 77%
High-risk cytogenetics: tyrosine kinase inhibitor: 6%, no: 1%
Length of follow-up: 59 months
Study design: Retrospective
Number of patients: 56
Tyrosine kinase inhibitor: Sorafenib
Age in tyrosine kinase inhibitor group (range): 24 (14–62)
Comparator: No tyrosine kinase inhibitor
Myeloablative conditioning: 100%
Complete remission at transplant: 100%
High-risk cytogenetics: 17%
Length of follow-up: 24 months